The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Immune Checkpoint Blockers Market Research Report 2025
Synopsis
The global Immune Checkpoint Blockers market was valued at US$ 17760 million in 2023 and is anticipated to reach US$ 54210 million by 2030, witnessing a CAGR of 17.0% during the forecast period 2024-2030.
North American market for Immune Checkpoint Blockers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Immune Checkpoint Blockers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Immune Checkpoint Blockers include Bristol Myers Squibb, Merck, AstraZeneca and Roche, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Immune Checkpoint Blockers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Checkpoint Blockers.
Report Scope
The Immune Checkpoint Blockers market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immune Checkpoint Blockers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immune Checkpoint Blockers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Merck
AstraZeneca
Roche
Segment by Type
Anti-PD-L1 Drug
Anti-PD-1 Drug
CTLA4
Segment by Application
Lung Cancer
Colorectal Cancer
BreastCancer
Prostate Cancer
Melanoma
Blood Cancers
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Immune Checkpoint Blockers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Immune Checkpoint Blockers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Immune Checkpoint Blockers market was valued at US$ 17760 million in 2023 and is anticipated to reach US$ 54210 million by 2030, witnessing a CAGR of 17.0% during the forecast period 2024-2030.
North American market for Immune Checkpoint Blockers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Immune Checkpoint Blockers is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Immune Checkpoint Blockers include Bristol Myers Squibb, Merck, AstraZeneca and Roche, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Immune Checkpoint Blockers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Checkpoint Blockers.
Report Scope
The Immune Checkpoint Blockers market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immune Checkpoint Blockers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immune Checkpoint Blockers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Merck
AstraZeneca
Roche
Segment by Type
Anti-PD-L1 Drug
Anti-PD-1 Drug
CTLA4
Segment by Application
Lung Cancer
Colorectal Cancer
BreastCancer
Prostate Cancer
Melanoma
Blood Cancers
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Immune Checkpoint Blockers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Immune Checkpoint Blockers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Immune Checkpoint Blockers Market Overview
1.1 Product Overview and Scope of Immune Checkpoint Blockers
1.2 Immune Checkpoint Blockers Segment by Type
1.2.1 Global Immune Checkpoint Blockers Market Value Comparison by Type (2024-2030)
1.2.2 Anti-PD-L1 Drug
1.2.3 Anti-PD-1 Drug
1.2.4 CTLA4
1.3 Immune Checkpoint Blockers Segment by Application
1.3.1 Global Immune Checkpoint Blockers Market Value by Application: (2024-2030)
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 BreastCancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancers
1.4 Global Immune Checkpoint Blockers Market Size Estimates and Forecasts
1.4.1 Global Immune Checkpoint Blockers Revenue 2019-2030
1.4.2 Global Immune Checkpoint Blockers Sales 2019-2030
1.4.3 Global Immune Checkpoint Blockers Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Immune Checkpoint Blockers Market Competition by Manufacturers
2.1 Global Immune Checkpoint Blockers Sales Market Share by Manufacturers (2019-2024)
2.2 Global Immune Checkpoint Blockers Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Immune Checkpoint Blockers Average Price by Manufacturers (2019-2024)
2.4 Global Immune Checkpoint Blockers Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Immune Checkpoint Blockers, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Immune Checkpoint Blockers, Product Type & Application
2.7 Immune Checkpoint Blockers Market Competitive Situation and Trends
2.7.1 Immune Checkpoint Blockers Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Immune Checkpoint Blockers Players Market Share by Revenue
2.7.3 Global Immune Checkpoint Blockers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Immune Checkpoint Blockers Retrospective Market Scenario by Region
3.1 Global Immune Checkpoint Blockers Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Immune Checkpoint Blockers Global Immune Checkpoint Blockers Sales by Region: 2019-2030
3.2.1 Global Immune Checkpoint Blockers Sales by Region: 2019-2024
3.2.2 Global Immune Checkpoint Blockers Sales by Region: 2025-2030
3.3 Global Immune Checkpoint Blockers Global Immune Checkpoint Blockers Revenue by Region: 2019-2030
3.3.1 Global Immune Checkpoint Blockers Revenue by Region: 2019-2024
3.3.2 Global Immune Checkpoint Blockers Revenue by Region: 2025-2030
3.4 North America Immune Checkpoint Blockers Market Facts & Figures by Country
3.4.1 North America Immune Checkpoint Blockers Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Immune Checkpoint Blockers Sales by Country (2019-2030)
3.4.3 North America Immune Checkpoint Blockers Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Immune Checkpoint Blockers Market Facts & Figures by Country
3.5.1 Europe Immune Checkpoint Blockers Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Immune Checkpoint Blockers Sales by Country (2019-2030)
3.5.3 Europe Immune Checkpoint Blockers Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Immune Checkpoint Blockers Market Facts & Figures by Country
3.6.1 Asia Pacific Immune Checkpoint Blockers Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Immune Checkpoint Blockers Sales by Country (2019-2030)
3.6.3 Asia Pacific Immune Checkpoint Blockers Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Immune Checkpoint Blockers Market Facts & Figures by Country
3.7.1 Latin America Immune Checkpoint Blockers Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Immune Checkpoint Blockers Sales by Country (2019-2030)
3.7.3 Latin America Immune Checkpoint Blockers Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Immune Checkpoint Blockers Market Facts & Figures by Country
3.8.1 Middle East and Africa Immune Checkpoint Blockers Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Immune Checkpoint Blockers Sales by Country (2019-2030)
3.8.3 Middle East and Africa Immune Checkpoint Blockers Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Immune Checkpoint Blockers Sales by Type (2019-2030)
4.1.1 Global Immune Checkpoint Blockers Sales by Type (2019-2024)
4.1.2 Global Immune Checkpoint Blockers Sales by Type (2025-2030)
4.1.3 Global Immune Checkpoint Blockers Sales Market Share by Type (2019-2030)
4.2 Global Immune Checkpoint Blockers Revenue by Type (2019-2030)
4.2.1 Global Immune Checkpoint Blockers Revenue by Type (2019-2024)
4.2.2 Global Immune Checkpoint Blockers Revenue by Type (2025-2030)
4.2.3 Global Immune Checkpoint Blockers Revenue Market Share by Type (2019-2030)
4.3 Global Immune Checkpoint Blockers Price by Type (2019-2030)
5 Segment by Application
5.1 Global Immune Checkpoint Blockers Sales by Application (2019-2030)
5.1.1 Global Immune Checkpoint Blockers Sales by Application (2019-2024)
5.1.2 Global Immune Checkpoint Blockers Sales by Application (2025-2030)
5.1.3 Global Immune Checkpoint Blockers Sales Market Share by Application (2019-2030)
5.2 Global Immune Checkpoint Blockers Revenue by Application (2019-2030)
5.2.1 Global Immune Checkpoint Blockers Revenue by Application (2019-2024)
5.2.2 Global Immune Checkpoint Blockers Revenue by Application (2025-2030)
5.2.3 Global Immune Checkpoint Blockers Revenue Market Share by Application (2019-2030)
5.3 Global Immune Checkpoint Blockers Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bristol Myers Squibb
6.1.1 Bristol Myers Squibb Corporation Information
6.1.2 Bristol Myers Squibb Description and Business Overview
6.1.3 Bristol Myers Squibb Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bristol Myers Squibb Immune Checkpoint Blockers Product Portfolio
6.1.5 Bristol Myers Squibb Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Immune Checkpoint Blockers Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Corporation Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AstraZeneca Immune Checkpoint Blockers Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Roche
6.4.1 Roche Corporation Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Roche Immune Checkpoint Blockers Product Portfolio
6.4.5 Roche Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Immune Checkpoint Blockers Industry Chain Analysis
7.2 Immune Checkpoint Blockers Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Immune Checkpoint Blockers Production Mode & Process
7.4 Immune Checkpoint Blockers Sales and Marketing
7.4.1 Immune Checkpoint Blockers Sales Channels
7.4.2 Immune Checkpoint Blockers Distributors
7.5 Immune Checkpoint Blockers Customers
8 Immune Checkpoint Blockers Market Dynamics
8.1 Immune Checkpoint Blockers Industry Trends
8.2 Immune Checkpoint Blockers Market Drivers
8.3 Immune Checkpoint Blockers Market Challenges
8.4 Immune Checkpoint Blockers Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Immune Checkpoint Blockers Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Immune Checkpoint Blockers Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Immune Checkpoint Blockers Market Competitive Situation by Manufacturers in 2023
Table 4. Global Immune Checkpoint Blockers Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Immune Checkpoint Blockers Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Immune Checkpoint Blockers Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Immune Checkpoint Blockers Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Immune Checkpoint Blockers Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Immune Checkpoint Blockers, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Immune Checkpoint Blockers, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Immune Checkpoint Blockers, Product Type & Application
Table 12. Global Key Manufacturers of Immune Checkpoint Blockers, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Immune Checkpoint Blockers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Checkpoint Blockers as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Immune Checkpoint Blockers Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Immune Checkpoint Blockers Sales by Region (2019-2024) & (K Units)
Table 18. Global Immune Checkpoint Blockers Sales Market Share by Region (2019-2024)
Table 19. Global Immune Checkpoint Blockers Sales by Region (2025-2030) & (K Units)
Table 20. Global Immune Checkpoint Blockers Sales Market Share by Region (2025-2030)
Table 21. Global Immune Checkpoint Blockers Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Immune Checkpoint Blockers Revenue Market Share by Region (2019-2024)
Table 23. Global Immune Checkpoint Blockers Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Immune Checkpoint Blockers Revenue Market Share by Region (2025-2030)
Table 25. North America Immune Checkpoint Blockers Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Immune Checkpoint Blockers Sales by Country (2019-2024) & (K Units)
Table 27. North America Immune Checkpoint Blockers Sales by Country (2025-2030) & (K Units)
Table 28. North America Immune Checkpoint Blockers Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Immune Checkpoint Blockers Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Immune Checkpoint Blockers Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Immune Checkpoint Blockers Sales by Country (2019-2024) & (K Units)
Table 32. Europe Immune Checkpoint Blockers Sales by Country (2025-2030) & (K Units)
Table 33. Europe Immune Checkpoint Blockers Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Immune Checkpoint Blockers Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Immune Checkpoint Blockers Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Immune Checkpoint Blockers Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Immune Checkpoint Blockers Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Immune Checkpoint Blockers Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Immune Checkpoint Blockers Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Immune Checkpoint Blockers Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Immune Checkpoint Blockers Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Immune Checkpoint Blockers Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Immune Checkpoint Blockers Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Immune Checkpoint Blockers Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Immune Checkpoint Blockers Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Immune Checkpoint Blockers Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Immune Checkpoint Blockers Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Immune Checkpoint Blockers Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Immune Checkpoint Blockers Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Immune Checkpoint Blockers Sales (K Units) by Type (2019-2024)
Table 51. Global Immune Checkpoint Blockers Sales (K Units) by Type (2025-2030)
Table 52. Global Immune Checkpoint Blockers Sales Market Share by Type (2019-2024)
Table 53. Global Immune Checkpoint Blockers Sales Market Share by Type (2025-2030)
Table 54. Global Immune Checkpoint Blockers Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Immune Checkpoint Blockers Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Immune Checkpoint Blockers Revenue Market Share by Type (2019-2024)
Table 57. Global Immune Checkpoint Blockers Revenue Market Share by Type (2025-2030)
Table 58. Global Immune Checkpoint Blockers Price (USD/Unit) by Type (2019-2024)
Table 59. Global Immune Checkpoint Blockers Price (USD/Unit) by Type (2025-2030)
Table 60. Global Immune Checkpoint Blockers Sales (K Units) by Application (2019-2024)
Table 61. Global Immune Checkpoint Blockers Sales (K Units) by Application (2025-2030)
Table 62. Global Immune Checkpoint Blockers Sales Market Share by Application (2019-2024)
Table 63. Global Immune Checkpoint Blockers Sales Market Share by Application (2025-2030)
Table 64. Global Immune Checkpoint Blockers Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Immune Checkpoint Blockers Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Immune Checkpoint Blockers Revenue Market Share by Application (2019-2024)
Table 67. Global Immune Checkpoint Blockers Revenue Market Share by Application (2025-2030)
Table 68. Global Immune Checkpoint Blockers Price (USD/Unit) by Application (2019-2024)
Table 69. Global Immune Checkpoint Blockers Price (USD/Unit) by Application (2025-2030)
Table 70. Bristol Myers Squibb Corporation Information
Table 71. Bristol Myers Squibb Description and Business Overview
Table 72. Bristol Myers Squibb Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Bristol Myers Squibb Immune Checkpoint Blockers Product
Table 74. Bristol Myers Squibb Recent Developments/Updates
Table 75. Merck Corporation Information
Table 76. Merck Description and Business Overview
Table 77. Merck Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Merck Immune Checkpoint Blockers Product
Table 79. Merck Recent Developments/Updates
Table 80. AstraZeneca Corporation Information
Table 81. AstraZeneca Description and Business Overview
Table 82. AstraZeneca Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. AstraZeneca Immune Checkpoint Blockers Product
Table 84. AstraZeneca Recent Developments/Updates
Table 85. Roche Corporation Information
Table 86. Roche Description and Business Overview
Table 87. Roche Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Roche Immune Checkpoint Blockers Product
Table 89. Roche Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Immune Checkpoint Blockers Distributors List
Table 93. Immune Checkpoint Blockers Customers List
Table 94. Immune Checkpoint Blockers Market Trends
Table 95. Immune Checkpoint Blockers Market Drivers
Table 96. Immune Checkpoint Blockers Market Challenges
Table 97. Immune Checkpoint Blockers Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Immune Checkpoint Blockers
Figure 2. Global Immune Checkpoint Blockers Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Immune Checkpoint Blockers Market Share by Type in 2023 & 2030
Figure 4. Anti-PD-L1 Drug Product Picture
Figure 5. Anti-PD-1 Drug Product Picture
Figure 6. CTLA4 Product Picture
Figure 7. Global Immune Checkpoint Blockers Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Immune Checkpoint Blockers Market Share by Application in 2023 & 2030
Figure 9. Lung Cancer
Figure 10. Colorectal Cancer
Figure 11. BreastCancer
Figure 12. Prostate Cancer
Figure 13. Melanoma
Figure 14. Blood Cancers
Figure 15. Global Immune Checkpoint Blockers Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Immune Checkpoint Blockers Market Size (2019-2030) & (US$ Million)
Figure 17. Global Immune Checkpoint Blockers Sales (2019-2030) & (K Units)
Figure 18. Global Immune Checkpoint Blockers Average Price (USD/Unit) & (2019-2030)
Figure 19. Immune Checkpoint Blockers Report Years Considered
Figure 20. Immune Checkpoint Blockers Sales Share by Manufacturers in 2023
Figure 21. Global Immune Checkpoint Blockers Revenue Share by Manufacturers in 2023
Figure 22. The Global 5 and 10 Largest Immune Checkpoint Blockers Players: Market Share by Revenue in 2023
Figure 23. Immune Checkpoint Blockers Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 24. Global Immune Checkpoint Blockers Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America Immune Checkpoint Blockers Sales Market Share by Country (2019-2030)
Figure 26. North America Immune Checkpoint Blockers Revenue Market Share by Country (2019-2030)
Figure 27. U.S. Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe Immune Checkpoint Blockers Sales Market Share by Country (2019-2030)
Figure 30. Europe Immune Checkpoint Blockers Revenue Market Share by Country (2019-2030)
Figure 31. Germany Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Immune Checkpoint Blockers Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific Immune Checkpoint Blockers Revenue Market Share by Region (2019-2030)
Figure 38. China Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Australia Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Taiwan Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Indonesia Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Thailand Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Malaysia Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Philippines Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America Immune Checkpoint Blockers Sales Market Share by Country (2019-2030)
Figure 49. Latin America Immune Checkpoint Blockers Revenue Market Share by Country (2019-2030)
Figure 50. Mexico Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Brazil Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Argentina Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East & Africa Immune Checkpoint Blockers Sales Market Share by Country (2019-2030)
Figure 54. Middle East & Africa Immune Checkpoint Blockers Revenue Market Share by Country (2019-2030)
Figure 55. Turkey Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. U.A.E Immune Checkpoint Blockers Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of Immune Checkpoint Blockers by Type (2019-2030)
Figure 59. Global Revenue Market Share of Immune Checkpoint Blockers by Type (2019-2030)
Figure 60. Global Immune Checkpoint Blockers Price (USD/Unit) by Type (2019-2030)
Figure 61. Global Sales Market Share of Immune Checkpoint Blockers by Application (2019-2030)
Figure 62. Global Revenue Market Share of Immune Checkpoint Blockers by Application (2019-2030)
Figure 63. Global Immune Checkpoint Blockers Price (USD/Unit) by Application (2019-2030)
Figure 64. Immune Checkpoint Blockers Value Chain
Figure 65. Immune Checkpoint Blockers Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
